Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Comment: Niraparib for ovarian cancer
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Niraparib for ovarian cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Promising results in metastatic bladder cancer using immunotherapy
Dr Matthew Galsky - Mount Sinai, New York, USA
Promising results in metastatic bladder cancer using immunotherapy ( Dr Matthew Galsky - Mount Sinai, New York, USA )
10 Oct 2016
ESMO 2016: Expert discussion on prostate cancer: Treatment safety and...
Prof Bertrand Tombal and Dr Mark Beresford
ESMO 2016: Expert discussion on prostate cancer: Treatment safety and predictive markers ( Prof Bertrand Tombal and Dr Mark Beresford )
9 Oct 2016
Advances for NSCLC in review
Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab plus chemo as firstline therapy for NSCLC
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Firstline pembrolizumab plus chemo improves NSCLC outcomes
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
Firstline pembrolizumab for metastatic urothelial cancer
Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
9 Oct 2016
Dabrafenib shows higher response and lower toxicity in paediatric brain cancer...
Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders...
Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial ( Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA )
8 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation